Status: Not yet recruiting
"Efesovir" (FS-1) for COVID-19, Phase 2
Study of the efficacy and safety of the new drug "Efesovir" in comparison with the drug "Remdesivir" in the treatment of patients hospitalized with COVID-19. The hypothesis of clinical study is the clinical efficacy of new drug "Efesovir" is 10% to 30% higher than of "Remdesivir".
Participants needed: 62
Trial details
Phase: Phase 2Age: 18-59Biological sex: AllType: InterventionalSponsor: Scientific Center for Anti-infectious Drugs, KazakhstanUpdated: Apr 17, 2024Locations: 1
Eligibility criteria
polymerase chain reaction (PCR) confirmed coronavirus infection (COVID-19) in ho... [+3]
age less than 18 years old and over 59 years old [+16]